T3 PHARMACEUTICALS
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 PHARMACEUTICALS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2015-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.t3pharma.com
Total Employee:
1+
Status:
Active
Contact:
+410612672074
Email Addresses:
[email protected]
Total Funding:
37 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving SSL By Default Google Maps LetsEncrypt Apple Mobile Web App Capable QUIC Google No Translate TYPO3
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Cellics Therapeutics
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines.
GFBiochemicals
GFBiochemicals company to produce levulinic acid at commercial scale directly from biomass.
Mogrify
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.
Okomera
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies.
Polymateria
Polymateria is a startup advancing science to help nature deal with plastic pollution.
Proto Axiom
Proto Axiom on-shores pre-clinical R&D expertise to bridge the gap.
Qubit Pharmaceuticals
Qubit Pharmaceuticals is an EIT Health Headstart laureate and is incubated at Paris Biotech Santé.
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - T3 Pharmaceuticals
Swiss Economic Award
Swiss Economic Award investment in Grant - T3 Pharmaceuticals
Reference Capital SA
Reference Capital SA investment in Series C - T3 Pharmaceuticals
Wille Finance
Wille Finance investment in Series C - T3 Pharmaceuticals
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - T3 Pharmaceuticals
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - T3 Pharmaceuticals
Reference Capital SA
Reference Capital SA investment in Series B - T3 Pharmaceuticals
Swiss Federal Commission for Innovation and Technology
Swiss Federal Commission for Innovation and Technology investment in Series A - T3 Pharmaceuticals
Official Site Inspections
http://www.t3pharma.com Semrush global rank: 11.21 M Semrush visits lastest month: 222
- Host name: s007.cyon.net
- IP address: 149.126.4.16
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "T3 Pharmaceuticals"
Board of Directors - T3 Pharma
Dr. Frank Kalkbrenner. Member of the Board of Directors Frank is the Global Head of the Boehringer Ingelheim Venture Fund. He served as board member of STAT Diagnostica (acquired by Qiagen in 2018), Hookipa Biotech (IPO at …See details»
Boehringer acquires T3 Pharma | Boehringer Ingelheim
Nov 22, 2023 T3 Pharma, founded in 2015 as a spin-off from the Biozentrum of the University of Basel, is a biotechnology company developing bacteria-based immuno-oncology therapies to treat solid tumors.See details»
management - T3 Pharma
Dr. Claire Barton. Chief Medical Officer Claire is a medical oncologist/pharmaceutical physician specializing in the clinical development of products for oncology indications.See details»
T3 Pharmaceuticals - Crunchbase Company Profile
T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. T3 Pharmaceuticals may be growing as it has been acquired by Boehringer Ingelheim, a transaction that typically indicates a …See details»
T3 Pharmaceuticals AG - Drug pipelines, Patents, Clinical trials
Www.t3pharma.com. Startups | Subsidiary Company | 2015 | Switzerland | < 10 | www.t3pharma.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
T3 Pharmaceuticals Company Profile 2024: Valuation, Investors ...
T3 Pharmaceuticals General Information Description. Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery …See details»
Boehringer Ingelheim acquires T3 Pharma for $509m
Nov 23, 2023 T3 Pharma will remain headquartered near Basel, Switzerland, with operations being kept in the region. As part of the acquisition, Boehringer Ingelheim will add T3 Pharma’s lead product – T3P-Y058-739 – to its portfolio.See details»
T3 Pharmaceuticals AG – Swiss Biotech
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments based on live bacteria. T3 Pharmaceuticals was acquired by Boehringer Ingelheim on 22 November 2023.See details»
T3 Pharma acquired by Boehringer Ingelheim for CHF 450 Million …
Nov 23, 2023 In a strategic move to fortify its position in the rapidly evolving field of immuno-oncology, Boehringer Ingelheim has successfully acquired T3 Pharma, a leading Swiss …See details»
T3 Pharma acquired by Boehringer Ingelheim for up to …
Nov 22, 2023 Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma – one of the first companies that BaseLaunch has financed – for an amount of up to CHF 450 million Swiss francs. T3 Pharma …See details»
T3 Pharma at a glance
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for …See details»
Onkologie: Deutscher Konzern bezahlt 450 Millionen für Basler …
Nov 22, 2023 Boehringer Ingelheim übernimmt die T3 Pharma mit Sitz in Allschwil. Laut der Mitteilung dazu bezahlt der deutsche Pharmakonzern 450 Millionen Franken für das 2015 …See details»
T3 Pharma - Company Profile - Tracxn
Nov 8, 2024 T3 Pharma ranks 248th among 2363 active competitors. 852 of its competitors are funded while 547 have exited. Overall, T3 Pharma and its competitors have raised over …See details»
T3 Pharma raises 25M CHF to advance bacterial cancer therapy …
Jul 22, 2020 T3 Pharmaceuticals AG Email: [email protected] Instinctif Partners (for English-speaking and International media) Dr Christelle Kerouedan / Dr Katie Duffell Tel: +44 …See details»
Boehringer backs T3 to take bacterial cancer therapy into clinic
Jul 22, 2020 T3 Pharmaceuticals has raised CHF 25 million ($27 million) to take its lead bacterial cancer therapy into the clinic. Boehringer Ingelheim Venture Fund (BIVF) co-led the …See details»
news - T3 Pharma
Nov 22, 2023 T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.See details»
T3 Pharma: Bacterial cancer treatment on the path to enter clinical ...
Jul 22, 2020 The Basel-based biotech company and Biozentrum spin-off T3 Pharmaceuticals AG is breaking new ground in the treatment of cancer by using live bacteria. The closing of the …See details»
technology - T3 Pharma
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria …See details»
pipeline - T3 Pharma
T3P-Y058-739 is T3 Pharma's lead asset with a mode of action on inducing a highly specific immune response selectively within solid tumours. Its way of functioning is shown in the …See details»